T.Rx Capital, a newly formed venture capital firm dedicated to early-stage healthcare innovation, has announced the close of its first fund, T.Rx Capital Fund I, at $77.5 million. The fund is focused on supporting visionary founders who are building at the intersection of technology and biology, with investments spanning biotechnology, techbio, and technology-enabled healthcare services.
The fund attracted strong interest from a diverse global investor base, comprising institutional allocators, family offices, and high-net-worth individuals from North America, Europe, the Middle East, and Asia. Notably, several prominent figures in the venture and life sciences sectors participated, including individual founders from Polaris Partners, Lux Capital, Third Rock Ventures, ARCH Venture Partners, and Dr. Robert Langer, who also serves as Executive Chairman of T.Rx Capital.
The firm was co-founded by Michael Langer, Dr. Corey McCann, and Dr. Kwesi Frimpong-Boateng, each bringing extensive experience in creating, funding, scaling, and guiding healthcare companies through successful transactions. Their combined expertise positions T.Rx Capital to identify and nurture companies with the potential to transform patient care and redefine how technology and biology converge in the healthcare industry.
T.Rx Capital is further strengthened by its venture partners, Dr. Debbie Lin, Vice President of Strategic Partnerships in Precision Oncology at Caris Life Sciences, and Dr. Liz Kwo, Chief Commercial Officer at Everly Health. Together, the leadership team and venture partners bring a blend of scientific, operational, and strategic insight that will help portfolio companies navigate the complex path from early innovation to market impact.
With Fund I now closed, T.Rx Capital is set to deploy capital into a new generation of healthcare startups, aiming to accelerate breakthroughs that can improve outcomes, expand access, and create lasting value in the global health ecosystem.
The firm is further strengthened by a talented advisory board, composed of world-renowned leaders in science, medicine, and industry. This includes:
– Dr. Robert Langer – Institute Professor at MIT and co-founder of more than 40 biotech companies, including Moderna
– Mark Levin – founder of Third Rock Ventures and of more than 30 biotech companies
– Dr. Freda Lewis-Hall – former Chief Medical Officer and Chief Patient Officer at Pfizer
– John Abele – co-founder and former co-Chairman of Boston Scientific
– Dr. Al Sandrock – CEO of Voyager Therapeutics and former Head of Research & Development at Biogen
– Peter Barton Hutt – former Chief Counsel of the US Food and Drug Administration, Senior Counsel at Covington & Burling
This leadership brings significant depth of experience and a proven track record of company-building, scientific excellence, and industry impact, positioning T.Rx Capital to support transformative innovation from inception through exit.
T.Rx Capital Fund I targets early-stage investments across healthcare, with a focus on company creation through Series B. The firm aims to build a concentrated portfolio of 10–15 companies, writing checks of $5–$10 million and taking active roles in company creation, scaling, and governance.
KEY QUOTES:
“We launched T.Rx Capital to identify and back the next generation of category-defining healthcare companies. As biology and technology converge, we see a historic opportunity to build scalable platforms that can fundamentally reshape disease treatment. We partner early with scientifically rigorous, execution-focused teams and provide the capital, network, and strategic support to help them build durable value from day one.”
Michael Langer
“2025 presents a unique window for biotech investment. After a reset in valuations and renewed capital discipline, we’re seeing breakthrough science accelerate alongside growing pharma demand for external innovation. With exit markets recovering, this is an exceptional time for venture capital to support the next wave of transformative biotech companies.”
Dr. Frimpong-Boateng
